MarketCap
STAAR Surgical Company STAA
$ 22.11
0.09%
Facebook
X
Telegram
STAAR Surgical Company Balance Sheet 2026-2009 | STAA
Brief balance sheet overview of STAAR Surgical Company
The balance sheet is assessed across five available annual reports spanning 2021 to 2026.
Assets added +30.6%, reaching $451.7 million from $345.8 million five periods earlier; annual growth near 5.5% remained solid.
Asset and liability trends were close, at +30.6% and +23.2%. Expansion did not materially reshape funding sources.
Internal capital represents 76.2% of the balance sheet, previously 75.6%. This is a strong capital position.
Cash exceeds interest-bearing debt, producing net debt of -$114.8 million. The balance sheet therefore carries a net cash position.
Cash represents 33.9% of assets versus 57.8% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$148 million. It should be assessed alongside historical profits and capital distributions.
Overall assessment
STAAR Surgical Company's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet STAAR Surgical Company
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-115 M | -105 M | -179 M | -82.7 M | -196 M | -118 M | - | -99.6 M | -13.6 M | -9.04 M | -8.4 M | -18.1 M | - | -15.3 M | -12.9 M | - | - |
Long Term Debt |
32.5 M | 34.8 M | 42 K | 210 K | 382 K | 366 K | - | 459 K | 531 K | 204 K | 468 K | 100 K | - | 500 K | 1.1 M | - | - |
Long Term Debt Current |
5.87 M | 3.89 M | 4.2 M | 3.52 M | 3.28 M | 2.7 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 12.5 M | - | 7.18 M | 5.91 M | 6.22 M | 5.44 M | 4.7 M | - | 5.1 M | 5.5 M | - | - |
Total Current Liabilities |
68.5 M | 70.3 M | 65 M | 51.7 M | 48.8 M | 34.5 M | - | 27.7 M | 19.1 M | 21.1 M | 16.4 M | 18.4 M | - | 17.9 M | 14 M | 13.4 M | - |
Total Liabilities |
107 M | 112 M | 103 M | 82.7 M | 87.2 M | 47 M | - | 34.9 M | 27.5 M | 24.1 M | 21.8 M | 23.1 M | - | 23 M | 19.5 M | 18.2 M | - |
Deferred Revenue |
- | - | - | - | - | 3.75 M | - | 1.28 M | 1.24 M | 439 K | 596 K | 373 K | - | 187 K | 152 K | - | - |
Retained Earnings |
-148 M | -67.6 M | -47.4 M | -68.7 M | -111 M | -142 M | - | -156 M | -161 M | -147 M | -140 M | -132 M | - | -132 M | -131 M | -132 M | - |
Total Assets |
452 M | 510 M | 489 M | 419 M | 346 M | 207 M | - | 167 M | 70.5 M | 63 M | 58.9 M | 61.9 M | - | 54.8 M | 49 M | 40.6 M | - |
Cash and Cash Equivalents |
153 M | 144 M | 183 M | 86.5 M | 200 M | 120 M | - | 104 M | 18.5 M | 14 M | 13 M | 23 M | - | 21.7 M | 16.6 M | 9.38 M | 6.33 M |
Book Value |
344 M | 397 M | 386 M | 336 M | 259 M | 160 M | - | 132 M | 42.9 M | 38.8 M | 37.1 M | 38.8 M | - | 31.8 M | 29.5 M | 22.4 M | - |
Total Shareholders Equity |
344 M | 397 M | 386 M | 336 M | 262 M | 160 M | - | 132 M | 42.9 M | 37.9 M | 37.1 M | 38.9 M | - | 31.7 M | 29.5 M | 22.4 M | 21.1 M |
All numbers in USD currency
Quarterly Balance Sheet STAAR Surgical Company
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
32.5 M | 31.2 M | 34.8 M | 33.8 M | 35.4 M | 33.1 M | 34.8 M | 35.4 M | 31.5 M | 31.1 M | 42 K | 84 K | 125 K | 167 K | 210 K | 252 K | 295 K | 338 K | 382 K | 21 K | 25 K | 28 K | 366 K | 73 K | 108 K | 132 K | - | 471 K | 580 K | 656 K | 459 K | 459 K | 459 K | 459 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
107 M | 98.8 M | 112 M | 103 M | 101 M | 107 M | 112 M | 109 M | 104 M | 99.7 M | 103 M | 92.9 M | 87 M | 80 M | 82.7 M | 74.5 M | 76.7 M | 74.9 M | 87.2 M | 75.5 M | 59.8 M | 51.6 M | 47.6 M | 48.3 M | 43.4 M | 41.8 M | - | 43.4 M | 41.6 M | 39.9 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | 25 M | 27.5 M | 27.5 M | 27.5 M | 27.6 M | 27.5 M | 27.5 M | 27.5 M | 21.8 M | 22.4 M | 20.5 M | 20.5 M | 23.1 M | 22.2 M | 22.5 M | 23 M | - | 21.7 M | 20 M | 20 M | 23 M | 23 M | 23 M | 23 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M |
Retained Earnings |
-148 M | -143 M | -67.6 M | -130 M | -139 M | -122 M | -67.6 M | -33.3 M | -43.3 M | -50.7 M | -47.4 M | -55.1 M | -63.9 M | -69.9 M | -68.7 M | -78.5 M | -88.8 M | -102 M | -111 M | -116 M | -122 M | -131 M | -142 M | -139 M | -143 M | -142 M | - | -148 M | -151 M | -154 M | -156 M | -156 M | -156 M | -156 M | -161 M | -161 M | -161 M | -161 M | -159 M | -159 M | -159 M | -159 M | -140 M | -146 M | -144 M | -143 M | -132 M | -138 M | -135 M | -133 M | - | -131 M | -132 M | -132 M | -132 M | -132 M | -132 M | -132 M | -131 M | -131 M | -131 M | -131 M |
Total Assets |
452 M | 451 M | 510 M | 456 M | 438 M | 457 M | 510 M | 538 M | 513 M | 493 M | 489 M | 472 M | 441 M | 419 M | 419 M | 395 M | 376 M | 351 M | 346 M | 325 M | 294 M | 266 M | 208 M | 235 M | 218 M | 207 M | - | 193 M | 186 M | 177 M | 167 M | 167 M | 167 M | 167 M | 67.9 M | 70.5 M | 70.5 M | 70.5 M | 65.5 M | 65.4 M | 65.4 M | 65.4 M | 58.9 M | 61.9 M | 60.3 M | 56.8 M | 61.9 M | 62.8 M | 64.4 M | 64.3 M | - | 59.5 M | 54.7 M | 52.7 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 49 M | 49 M | 49 M | 49 M |
Cash and Cash Equivalents |
144 M | 132 M | 86.5 M | 176 M | 167 M | 173 M | 144 M | 164 M | 193 M | 224 M | 183 M | 127 M | 94.7 M | 90 M | 86.5 M | 129 M | 202 M | 193 M | 200 M | 196 M | 173 M | 162 M | 120 M | 128 M | 116 M | 111 M | - | 112 M | 103 M | 102 M | 104 M | 104 M | 104 M | 104 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 14 M | 14 M | 14 M | 14 M | 13 M | 16.1 M | 15.3 M | 10.8 M | 23 M | 18.4 M | 19.2 M | 21.1 M | - | 23.4 M | 19.7 M | 19.2 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M |
Book Value |
344 M | 352 M | 397 M | 354 M | 337 M | 350 M | 397 M | 428 M | 409 M | 393 M | 386 M | 379 M | 354 M | 339 M | 336 M | 320 M | 299 M | 276 M | 259 M | 249 M | 235 M | 214 M | 160 M | 186 M | 175 M | 165 M | - | 149 M | 144 M | 137 M | 132 M | 132 M | 132 M | 132 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | 37.9 M | 37.9 M | 37.9 M | 37.9 M | 37.1 M | 39.5 M | 39.8 M | 36.3 M | 38.9 M | 40.6 M | 41.8 M | 41.3 M | - | 37.8 M | 34.7 M | 32.6 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M |
Total Shareholders Equity |
397 M | 352 M | 336 M | 354 M | 337 M | 350 M | 397 M | 428 M | 409 M | 393 M | 386 M | 379 M | 358 M | 343 M | 336 M | 323 M | 299 M | 276 M | 259 M | 249 M | 235 M | 214 M | 160 M | 186 M | 175 M | 165 M | - | 149 M | 144 M | 137 M | 132 M | 132 M | 132 M | 132 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | 37.9 M | 37.9 M | 37.9 M | 37.9 M | 37.1 M | 39.5 M | 39.8 M | 36.3 M | 38.9 M | 40.6 M | 41.8 M | 41.3 M | - | 37.8 M | 34.7 M | 32.6 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of STAAR Surgical Company, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 36.38 | 0.54 % | $ 1.74 B |  USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
The Cooper Companies
COO
|
$ 71.17 | 0.3 % | $ 14.2 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 90.49 | 1.06 % | $ 5.35 B | USA |
 |
AtriCure
ATRC
|
$ 48.54 | 2.28 % | $ 2.32 B | USA |
 |
Nephros
NEPH
|
$ 4.55 | 5.57 % | $ 48.3 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 103.96 | 0.03 % | $ 4.9 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 179.87 | 0.74 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 7.93 | 0.38 % | $ 352 M | USA |
 |
AngioDynamics
ANGO
|
$ 15.85 | 0.44 % | $ 658 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
ICU Medical
ICUI
|
$ 175.1 | 0.43 % | $ 4.31 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.04 | 0.12 % | $ 249 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 120.25 | 3.37 % | $ 3.85 B | USA |
 |
STERIS plc
STE
|
$ 233.78 | 0.35 % | $ 23 B | USA |
 |
Pro-Dex
PDEX
|
$ 62.56 | 1.6 % | $ 206 B | USA |
 |
Baxter International
BAX
|
$ 26.13 | 0.81 % | $ 13.4 B | USA |
 |
Repligen Corporation
RGEN
|
$ 176.27 | 0.96 % | $ 9.91 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 47.57 | 0.04 % | $ 3.21 B | USA |
 |
ResMed
RMD
|
$ 240.33 | 1.94 % | $ 35 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 372.6 | 1.51 % | $ 133 B | USA |
 |
electroCore
ECOR
|
$ 9.63 | 1.54 % | $ 81.7 K | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.12 | 0.72 % | $ 2.22 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.5 | 0.36 % | $ 41 M | USA |
 |
Alcon
ALC
|
$ 72.01 | 0.07 % | $ 35.5 B |  Schweiz |
 |
West Pharmaceutical Services
WST
|
$ 337.47 | 0.11 % | $ 24.4 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 27.13 | 0.02 % | $ 4.56 B | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.48 | 0.33 % | $ 67.8 M |  Israel |
 |
Stereotaxis
STXS
|
$ 1.45 | 0.34 % | $ 132 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.23 | 0.94 % | $ 149 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.6 | 0.13 % | $ 265 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 139.67 | 1.42 % | $ 6.23 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.45 | 0.99 % | $ 1.82 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 189.52 | 0.74 % | $ 54.5 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.73 | 1.14 % | $ 21.9 M | USA |
 |
Utah Medical Products
UTMD
|
$ 72.77 | 1.35 % | $ 236 M | USA |